Open-label evaluation of a novel skin brightening system containing 0.01% decapeptide-12 in combination with 20% buffered glycolic acid for the treatment of mild to moderate facial melasma.
Ramírez. Sandra P SP; Carvajal. Alfonso C AC; Salazar. Juan C JC; Arroyave. Gladys G; Flór...
A 16‑week open‑label study in 33 Hispanic women with mild‑to‑moderate melasma found that a skin‑brightening routine containing a 0.01% decapeptide‑12 cream, an antioxidant cleanser, a 20% buffered glycolic‑acid lotion, and SPF 30 sunscreen was safe and cut the melasma severity score by about 60%.